tiprankstipranks
Trending News
More News >

Madrigal Pharmaceuticals price target raised to $420 from $394 at Canaccord

Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $420 from $394 and keeps a Buy rating on the shares. The firm said they reported financial results and business highlights for Q1. Product sales of Rezdiffra beat expectations for both the firm and the Street.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue